Loading patent…
AssigneeGenentech, Inc.
InventorsMahrukh Huseni, Joanna E. Klementowicz, Yijin Li, Li-Fen Liu, Sanjeev Mariathasan, Mark Merchant, Luciana Molinero, Lifen Wang, Nathaniel West, Patrick Williams, Chi Yung Yuen, Edward Namserk Cha, Yulei Wang
Estimating the term…
This application discloses methods and compositions for use in treating cancer, including breast cancer (such as metastatic triple negative breast cancer, mTNBC), urothelial carcinoma, renal cell carcinoma, and liver cancer (hepatocellular carcinoma, HCC) with the combination of a PD-1 axis binding antagonist (e.g., a PD-L1 binding antibody such as atezolizumab) and an IL6 antagonist (e.g. an anti-IL6 receptor antibody such as tocilizumab), optionally further comprising a VEGF antagonist (e.g. an anti-VEGF antibody such as bevacizumab). Optionally, the patient has C-reactive protein (CRP) and/or IL-6 level(s) above the upper limit of normal. Optionally, the cancer is PD-L1 positive.
A method of treating a cancer patient comprising administering to the patient a combination of an IL-6 antagonist and a PD-1 axis binding antagonist in an amount effective to treat the cancer.
A method of treating a cancer patient comprising administering to the patient a combination of an anti-IL6 receptor antibody and an anti-PD-L1 antibody in an amount effective to treat the cancer.
A method of treating a cancer patient with C-reactive protein (CRP) level above the upper limit of normal comprising administering to the patient a combination of an anti-IL6 receptor antibody and an anti-PD-L1 antibody in an amount effective to treat the cancer.
A method of treating advanced urothelial carcinoma in a cancer patient comprising administering to the patient a combination of tocilizumab and atezolizumab in an amount effective to treat the cancer.
A method of treating triple negative breast cancer (TNBC) in a cancer patient comprising administering to the patient a combination of tocilizumab, atezolizumab, and chemotherapy in an amount effective to treat the cancer.
A method of reducing or preventing therapeutic resistance to a PD-1 axis binding antagonist in a cancer patient comprising administering the PD-1 axis binding antagonist to the patient in combination with an IL-6 antagonist in an amount effective to treat the cancer.
A method of treating cancer in a cancer patient comprising administering to the patient a combination of atezolizumab, bevacizumab, and tocilizumab in an amount effective to treat the cancer.
Dependencies are inferred from the claim text.